Cyient DLM is a high-mix, low-volume electronics manufacturing services provider whose economics depend on qualification-heavy, design-led work in aerospace, defence, medical and industrial electronics. The business is not a commodity assembler. It operates two models: build-to-print, where the customer owns the design and bill of materials, and build-to-spec/electronic products, where Cyient DLM takes design, engineering and supply-chain responsibility. The Q2 FY27 call added a sharper distinction: the legacy B2S work is now being organised as electronic products, with four large programmes worth close to USD1 billion that are mostly not yet in the order book. That is the long-dated option; the near-term thesis is still the conversion of the record order book into revenue and the recovery of margins from the Q2 trough.
The current operating picture is strong on revenue and weaker on margin. Q2 FY27 revenue was INR3,931 million, up 26.5% year-on-year, and H1 FY27 revenue was INR7,669 million, up 30.2%. That follows a FY26 in which revenue fell 17% to INR12,615 million after a large defence order completed. The order book reached INR2,813 crore at Q2 FY27 with a 1.6x book-to-bill ratio, up from INR2,598 crore in Q1. Management says the order book executes over 18-24 months, which gives visibility but not a precise quarterly schedule. The revenue mix is still concentrated: Aerospace was 47% of Q2 revenue and grew 62% year-on-year; Industrial was 31% and grew 29%; MedTech was 14% and grew 14%; Defence was 7% and grew 13%. Aerospace and Defence together were 54% of revenue, so the Honeywell and Thales ramp remains the main swing factor.
Margins are the central debate. FY26 normalized EBITDA margin was 10.3%, and Q1 FY27 was 10.5%, which made the double-digit margin look structural. Q2 FY27 broke that run: EBITDA margin fell to 8.7%, and H1 FY27 was 9.6%. Management guides FY27 to a high-single-digit level, around 9% and within a 9-10% range, with double-digit margin from FY28. The stated cause is deliberate expensed investment in sales and marketing, plus product-development costs that are not capitalised. The operating-leverage thesis therefore shifts out by a year: the question is not whether Q1 FY27's 10.5% was real, but whether the S&M cost base is now largely in place and can be absorbed by FY28 revenue. Management says it will not add more sales and marketing costs until quarterly revenue doubles, which is a clear cost discipline marker. If that holds, the FY28 double-digit target is credible; if revenue slips, the cost base will keep margins in the high single digits.
The earnings path depends on three measurable items. First, revenue growth must stay above 30% in H2 FY27 to meet the indicated 30-35% FY27 range; Q2's 26.5% was below that, so Q3 and Q4 are the test. Second, the order book must convert, not just grow. The record INR2,813 crore book is 18-24 months of work, and supply-chain shortages and memory lead times can delay conversion. Third, working capital must keep improving. Net working capital fell to 153 days from 161 in Q1, DSO improved to 73 days and DPO rose to 68, producing INR172 million of operating free cash flow in Q2. That is better, but still above the 100-120 day target and inventory days remain 162. Positive cash conversion is essential because the company is funding growth internally.
Capital allocation is conservative. Routine capex has been guided at 1%-2% of revenue, and management says no additional capex is needed for the FY27-FY29 Expand phase beyond regular annual spend. The B2S lab expansion from 6,000 to 15,000 square feet was completed in Q1 FY27. The Mysore land acquisition was a long-lead infrastructure step, not a current large capex programme. The main capital-allocation risk is not a new factory; it is working capital. If inventory stays elevated while revenue ramps, free cash flow will remain weak even with modest capex.
Management delivery is mixed. The FY26 double-digit margin promise was delivered, and the book-to-bill commitment was met. The Q4 FY26 year-on-year revenue growth promise was missed, and the Q2 FY27 call has now reset FY27 margin guidance lower and pushed the four large B2S programmes to FY29-FY30 production. That does not invalidate the business, but it means investors should distinguish between the order book, which is real, and the timing of revenue and margin, which has repeatedly slipped. The company also reported Q2 PAT of INR340 million after a INR182 million earnout reversal; normalized PAT was INR158 million, so reported earnings overstate the underlying quarter.
The investment thesis is therefore a delayed operating-leverage story, not a current margin story. The business has the certifications, customer relationships and order book to grow revenue. The FY27 margin guide of 9-10% is a reset, and the FY28 double-digit target is the key milestone. The B2S/electronic-products pipeline is an option: four programmes close to USD1 billion, partly contracted, not in the order book, with production from FY29 and scale from FY30. That option is valuable but too far away to support FY27 earnings.
Falsifiers are clear. A FY27 EBITDA margin below 9%, or a failure to reach double digit in FY28, would undercut the operating-leverage thesis. H2 FY27 revenue growth below 30% would suggest the order book is not converting on schedule. Net working capital staying above 153 days, or free cash flow turning negative again, would show the growth is consuming cash. A slip in the FY29 B2S production start would push the higher-margin mix further out. Conversely, evidence that Q3 and Q4 FY27 revenue growth is above 30%, FY27 margin lands at 9.5-10%, and B2S contracts start entering the order book would validate the delayed leverage path.
companyname: Cyient DLM Limited ticker: CYIENTDLM sector: Electronics Manufacturing Services (EMS) Cyient DLM is an integrated electronics manufacturing services (EMS) company that builds high-reliability electronic systems for aerospace, defence, medical, industrial, and automotive customers. It is a spin-off of Cyient Ltd, a global engineering and technology company, and was incorporated in 1993 as Rangsons Electronics before Cyient acquired a 74% stake in 2013 and eventually took full owners...
Read the full report →margin expansion, order book surge
Management guides FY27 EBITDA margin to a high-single-digit level, around 9% and within a 9-10% range, with double-digit EBITDA margin from FY28. It indicated FY27 revenue growth of 30-35% and H2 FY27 growth above 30%. Four electronic-products/B2S programmes worth close to USD1 billion are targeted for production from FY29 and scale from FY30 and are not in the order book; order-book execution is 18-24 months.
Guidance maintainedmixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Cyient DLM Limited and 4,900+ companies.
5-day free pass. No card required.